Curevac N.V. (CVAC)

$55.30 1.71 (3.19%)

16:00 EDT CVAC Stock Quote Delayed 30 Minutes

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today

By Chris MacDonald, InvestorPlace Contributor Aug 16, 2021

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 358,512

Day's Range 52.83 - 55.67

52-Week Range 43.00 - 151.80

Dividend & Yield N/A (N/A)

CVAC Stock Predictions, Articles, and Curevac N.V. News

From InvestorPlace
From the Web

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor, Today's Market Jun 17, 2021

So what did the stock market do today? All eyes were on a World Bank decision and big moves in RIDE and CVAC stocks.

CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today

By Robert Lakin, InvestorPlace Contributor Jun 17, 2021

CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jun 17, 2021

We're starting off the day with a look at the biggest pre-market stock movers for Thursday and it includes loads of medical stocks.

7 Best Vaccine Stocks for Their Pipeline Potential

By Faisal Humayun Jun 3, 2021

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer.

7 Global Stocks That Are Worth Adding to Your Portfolio

By Faisal Humayun May 20, 2021

Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer May 7, 2021

We're really starting to get into earnings season with many of the biggest pre-market stock movers today connected to earnings news.

9 New-on-Robinhood Stocks You Can Buy Now

By Josh Enomoto, InvestorPlace Contributor Oct 7, 2020

Here are the latest Robinhood stocks you can buy on the popular trading app, featuring well-rounded selections from several sectors.

CVAC Stock: CureVac Pops on Plans for Phase 2 Vaccine Trials

By Sarah Smith, Editor, Today's Market Sep 30, 2020

CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.

Germany Makes a $299 Million Bet on CureVac

By Will Ashworth, InvestorPlace Contributor Sep 18, 2020

CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

By Thomas Niel Sep 14, 2020

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:GSK) Inovio (NASDAQ:INO) Johnson & Johnson (NYSE:JNJ) Moderna (NASDAQ:MRNA) Novavax (NASDAQ:NVAX)

CureVac Stock Is Just Another Part of a Bigger Story

By Chris Markoch Sep 14, 2020

With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.

No Need to Rush Into CureVac Stock After Massive IPO Pop

By InvestorPlace Research Staff Sep 9, 2020

CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.

Why Science and Economics Might Justify CureVac

By Josh Enomoto, InvestorPlace Contributor Sep 9, 2020

Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?

Is CureVac a Buy on the Pullback? It Depends

By Thomas Niel Sep 3, 2020

Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.

Why CureVac Might Soar From Here

By Chris Lau, InvestorPlace Contributor Sep 2, 2020

The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed

Go Easy on CureVac Stock After Its Red-Hot Market Debut

By David Moadel, InvestorPlace Contributor Sep 1, 2020

CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.

CureVac Stock Has Been Hot Following Its Recent IPO

By Tezcan Gecgil, InvestorPlace Contributor Sep 1, 2020

CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.

CureVac Stock Soars After Talks of Supplying Vaccines for the EU

By Divya Premkumar, InvestorPlace Contributor Aug 28, 2020

CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states.

CureVac Is a Bet on a Safe and Effective Vaccine

By Mark R. Hake, CFA Aug 26, 2020

CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.